Hearts and Minds donates almost $10m to charity

Listed investment company Hearts and Minds Investments (ASX: HM1) will donate $5.1 million to 10 medical research this week, in addition to the $4.1 million it already donated in March. [Financial Standard]

Ally Selby

Hearts and Minds donates almost $10m to charity

September 1, 2020
Listed investment company Hearts and Minds Investments (ASX: HM1) will donate $5.1 million to 10 medical research this week, in addition to the $4.1 million it already donated in March. [Financial Standard]
Read Transcript

Listed investment company Hearts and Minds Investments (ASX: HM1) will donate $5.1 million to 10 charities this week, in addition to the $4.1 million it already donated in March.

HM1 and its participating fund managers forego any investment or management fees and instead donate 1.5% of its net tangible assets per annum to various medical research institutes and charities.

HM1's core fund managers, who provide the listed investment company with their three highest conviction ideas, include Will Vicars and Michael Messara from Caledonia Investments; Peter Cooper from Cooper Investors; Hamish Douglass from Magellan; Philip King from Regal Funds Management; David Paradice from Paradice Investments; and Hamish Corlett and Tom Cowan from TDM Growth Partners.

The $5.1 million will be split across 10 medical research houses and charities, including The Victor Chang Cardiac Research Institute; The Florey Institute of Neuroscience and Mental Health; Swinburne's Centre for Psychopharmacology; RPA Green Light Institute; Black Dog Institute; Orygen; Charlie Teo Foundation; MS Research Australia; Kids Critical Care at Westmead Hospital; and the Brain and Mind Centre within the University of Sydney.

"These donated monies will be used by the medical research organisations to fund important research into the prevention and treatment of chronic diseases and mental health disorders," HM1 said in its annual report.

"The current pandemic highlights the critical importance of medical research to global health outcomes and economic prosperity."

HM1 recently reported a pre-tax investment return of 26.1% for the year ending  June 30, significantly outperforming its global benchmark (MSCI World Net TR), which increased 4.8% over the financial year.

Since its inception in November 2018, HM1 has generated a pre-tax return of 51.3%, compared to the benchmark's 18.2% over the same nearly two year period.

It outperformed the same index by 19.7% over the past six months, returning 15.9% compared to the benchmark's -3.8%.

HM1 chief executive Paul Rayson believes this is in large thanks to the investment company's holdings in Tesla, which they have held since November last year.

"Tesla has been a standout, but we also invest in Appen which is up over 100%, we participated in Spotify, which is up over 75%, while Zillow Group, Microsoft, and our holdings in next tier tech companies have also performed well," he told Financial Standard.

The listed investment company's largest holding (as of June 30) is Mineral Resources (7.54%), followed by Zillow Group (6.96%), Alibaba (6.7%), and Spotify (5.76%).

More than 5% of the portfolio's holdings are invested in Tesla.

While the portfolio is concentrated in a relatively small number of securities (only 28 as of June 30), it is overweight to communications, technology and consumer discretionaries compared to its benchmark.

"These sectors have performed well over the past year or two, but no one can predict the future," Rayson said.

"The way our model works is that we invest in the highest conviction ideas from our fund managers."

It is underweight to financials, utilities, healthcare and materials compared to the MSCI World Index.

Only six of the companies that HM1 invests in have a market cap over ~$68 billion (US$50 billion), while its smallest holding has a market cap of  $650 million.

 

This article was originally featured on Financial Standard here.

Listed investment company Hearts and Minds Investments (ASX: HM1) will donate $5.1 million to 10 charities this week, in addition to the $4.1 million it already donated in March.

HM1 and its participating fund managers forego any investment or management fees and instead donate 1.5% of its net tangible assets per annum to various medical research institutes and charities.

HM1's core fund managers, who provide the listed investment company with their three highest conviction ideas, include Will Vicars and Michael Messara from Caledonia Investments; Peter Cooper from Cooper Investors; Hamish Douglass from Magellan; Philip King from Regal Funds Management; David Paradice from Paradice Investments; and Hamish Corlett and Tom Cowan from TDM Growth Partners.

The $5.1 million will be split across 10 medical research houses and charities, including The Victor Chang Cardiac Research Institute; The Florey Institute of Neuroscience and Mental Health; Swinburne's Centre for Psychopharmacology; RPA Green Light Institute; Black Dog Institute; Orygen; Charlie Teo Foundation; MS Research Australia; Kids Critical Care at Westmead Hospital; and the Brain and Mind Centre within the University of Sydney.

"These donated monies will be used by the medical research organisations to fund important research into the prevention and treatment of chronic diseases and mental health disorders," HM1 said in its annual report.

"The current pandemic highlights the critical importance of medical research to global health outcomes and economic prosperity."

HM1 recently reported a pre-tax investment return of 26.1% for the year ending  June 30, significantly outperforming its global benchmark (MSCI World Net TR), which increased 4.8% over the financial year.

Since its inception in November 2018, HM1 has generated a pre-tax return of 51.3%, compared to the benchmark's 18.2% over the same nearly two year period.

It outperformed the same index by 19.7% over the past six months, returning 15.9% compared to the benchmark's -3.8%.

HM1 chief executive Paul Rayson believes this is in large thanks to the investment company's holdings in Tesla, which they have held since November last year.

"Tesla has been a standout, but we also invest in Appen which is up over 100%, we participated in Spotify, which is up over 75%, while Zillow Group, Microsoft, and our holdings in next tier tech companies have also performed well," he told Financial Standard.

The listed investment company's largest holding (as of June 30) is Mineral Resources (7.54%), followed by Zillow Group (6.96%), Alibaba (6.7%), and Spotify (5.76%).

More than 5% of the portfolio's holdings are invested in Tesla.

While the portfolio is concentrated in a relatively small number of securities (only 28 as of June 30), it is overweight to communications, technology and consumer discretionaries compared to its benchmark.

"These sectors have performed well over the past year or two, but no one can predict the future," Rayson said.

"The way our model works is that we invest in the highest conviction ideas from our fund managers."

It is underweight to financials, utilities, healthcare and materials compared to the MSCI World Index.

Only six of the companies that HM1 invests in have a market cap over ~$68 billion (US$50 billion), while its smallest holding has a market cap of  $650 million.

 

This article was originally featured on Financial Standard here.

Disclaimer: This material has been prepared by Financial Standard, published on Sep 01, 2020. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
February 14, 2023

Bringing Equity and Diversity to Genomic Medicine

Professor Daniel MacArthur, Director of the Centre for Population Genomics has big goals to bring equity and diversity into genomic medicine in Australia, something surprisingly inadequate presently.

Read More
October 21, 2022

WEHI: Art of Science Online Exhibition 2022

WEHI has officially opened their interactive online exhibition, Art of Science, which features incredible biomedical images from WEHI researchers.

Read More
October 20, 2022

PMRI: Digital Education Platform Project - Pain Management

PMRI is developing digital pain education to support the emerging, current and future health workforce and improve the lives of patients with chronic pain.

Read More
September 16, 2022

Talking Tech: Matt Berriman, Founder of RealVC

Matt Berriman, founder of RealVC and ‘The Business of Sport’ panellist at 2022 Sohn Hearts & Minds Conference discusses his entrepreneurial learnings and the parallels between sports and business.

Read More
September 6, 2022

VCCRI: 'Heart in a Box'

An Australian method of preserving donated hearts has boosted the number of successful transplants across the world, with new research demonstrating similar survival rates to traditional transplants.

Read More
September 1, 2022

WEHI: Say Hi to the life-saving impact of medical research discoveries

HM1 beneficiary Walter and Eliza Hall Institute recently released a video dedicated to the life-saving impact of long-term medical research discoveries.

Read More
August 24, 2022

Cerebral Palsy Alliance: Changing the GAME

A research team at Cerebral Palsy Alliance is working to develop a world-first, early-intervention therapy approach for infants with cerebral palsy called ‘GAME’ (Goals, Activity, Motor Enrichment).

Read More
August 3, 2022

The Florey: New target in MND drug discovery

The Florey investigates how a previously underappreciated cell type potentially contributes to the progressive loss of motor neurons in Motor Neurone Disease (MND).

Read More
July 21, 2022

Remarkable Demo Day 2022: Disability-tech accelerator

Remarkable, Australia’s first disability-tech accelerator made possible by Cerebral Palsy Alliance, has released a video sharing the innovative products developed by the 2022 cohort.

Read More
July 11, 2022

Black Dog: Space 22

Black Dog Institute’s art-based researcher Professor Katherine Boydell is starring in an ABC documentary series, Space 22, hosted by Natalie Bassingthwaighte. The series follows those with lived experience of mental ill health.

Read More
June 21, 2022

WEHI: New findings could lead to cancer therapy without harmful side-effects

Researchers at WEHI have developed a way to potentially reduce the toxic side-effects of a type of immunotherapy, in findings that could overcome the pioneering treatment’s biggest limitation.

Read More
March 17, 2022

Victor Chang: Innovation Centre

COVID-19 may have stopped tours of Victor Chang's Innovation Centre but it certainly hasn’t slowed their scientists from making new discoveries as shown in this video with Sky News Australia.

Read More
February 24, 2022

Impact Video: Cerebral Palsy Alliance

This video features Professor Nadia Badawi AM, Professor Alistair McEwan, Paul Rayson and others discussing the incredible impact our partnership will have.

Read More
February 24, 2022

New Partnership with Cerebral Palsy Alliance

We’re excited to announce a new partnership with the Cerebral Palsy Alliance and are proud to be supporting this important research.

Read More
February 20, 2022

The Florey: What is 'Zoom Fatigue' and how to avoid it

The Florey has recently published new research that sheds light on the phenomenon of “zoom fatigue” – yes it’s a real thing! Listen to this podcast episode as Professor Bernhardt explains what it is and how to prevent it.

Read More
December 10, 2024

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
impact-podcasts
September 24, 2024

Asian Market Potential with Tom Naughton of Prusik

CIO Charlie Lanchester sits down with Tom Naughton, CIO of Prusik Investment Mgmt. Tom shares his investment philosophy, the opportunities and challenges in Asian markets, and how his 2023 conference stock pick, Swire Pacific (0019.HK), delivered an impressive 30% return.

Read More
investing
September 4, 2024

Building Hearts and Minds with Co-Founders Matthew Grounds and Guy Fowler

In this episode, co-founders Matthew Grounds AM and Guy Fowler OAM discuss their journey in building Hearts & Minds and its philanthropic model that has donated over $70 million to medical research.

Read More
investing
June 25, 2024

Navigating the Resource Sector with Jeremy Bond of Terra Capital

In this episode, we chat with Jeremy Bond, Founder of Terra Capital and HM1 Conference Fund Manager. Tune in for insights into the world of resource investments and the exciting opportunities that lie ahead.

Read More
investing
June 11, 2024

Prof. Nadia Badawi on Cerebral Palsy Breakthroughs and Neonatal Care

Dive deep into the groundbreaking work of Professor Nadia Badawi, an internationally recognised neonatologist and expert in Cerebral Palsy.

Read More
impact-podcasts
May 28, 2024

Investment Insights: Rikki Bannan on Top Picks and Trends

Join us for an engaging episode featuring Rikki Bannan, Portfolio Manager of IFM Investors and HM1 Conference Fund Manager. This episode explores Rikki's career journey, investment strategies, and her 2023 conference stock pick, Telix Pharmaceuticals (ASX.TLX).

Read More
investing
December 6, 2023

Peter Cooper talks building and instilling a culture of humility and excellence

In this episode, our guest is the renowned investor, Peter Cooper, founder and Chief Investment Officer of Cooper Investors (Core Fund Manager). A founding supporter of Hearts and Minds, Peter is a staunch advocate of our model and its philanthropic purpose, actively engaging in every facet of Hearts and Minds.

Read More
investing
November 28, 2023

Jun Bei Liu on her high conviction investment strategy

In this episode, HM1 Chief Investment Officer Charlie Lanchester is joined by Jun Bei Liu. Jun Bei is the Portfolio Manager of Tribeca’s Alpha Plus Fund and since taking over managing the Fund, she has quadrupled AUM.

Read More
investing
November 21, 2023

The world of rare genetic disease research

In this episode, we speak to Associate Professor Gina Ravenscroft. Gina is an Associate Professor in Neurogenetics at the Harry Perkins Institute of Medical Research in Perth. Her research interests are in rare genetic diseases, with a particular focus on neurogenetic diseases in babies and children.

Read More
impact-podcasts
November 14, 2023

Learn what makes a high conviction investment and how to avoid short-term noise

In this episode, our Core Fund Manager Magellan shares how they select top stocks for the HM1 portfolio.

Read More
investing
November 7, 2023

Delve into the world of kids critical care and trauma research

In thie episode, we are joined by Dr. Marino Festa, or Rino for short. He is the Medical Director of NSW Kids ECMO Referral Service and a senior specialist in Paediatric Intensive Care at Children’s Hospital at Westmead.

Read More
impact-podcasts
October 31, 2023

Where Regal's Phil King is searching for opportunities

HM1's CIO, Charlie Lanchester, talks to Phil King of Regal Funds about his passion for stocks, his ongoing search for opportunities, and some of the sectors he’s excited by right now. Phil King of Regal Funds, has been a tremendous supporter of Hearts & Minds since the beginning.

Read More
investing
October 24, 2023

Preventing recurrent miscarriages and birth defects

In this episode, CEO Paul Rayson is joined by renowned biomedical researcher Professor Sally Dunwoodie. Prof. Dunwoodie's groundbreaking work has revolutionised clinical practices and enabled genetic diagnostic tests worldwide. In 2017, her team achieved a double breakthrough with the potential to prevent recurrent miscarriages and various birth defects.

Read More
impact-podcasts
October 17, 2023

Nick Griffin on how he finds global winners

In this episode, CIO Charlie Lanchester chats with Nick Griffin, the founding partner and CIO of Munro Partners, one of HM1's Core Fund Managers. They go over his career to date, reflect on the lessons he’s learned, and trace the decisions that led to him starting Munro.

Read More
investing
October 10, 2023

How A/Prof Matt Call is teaching our body to kill cancer

In this episode, CEO Paul Rayson is joined by WEHI’s Associate Professor Matt Call to talk about his incredible research. Matt’s team teaches and trains the body's own immune cells to target and kill cancer cells.

Read More
impact-podcasts

No results found.

Please try a different search keyword or filter.